title: Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system.
abstract: BACKGROUND
  The Mirasol pathogen reduction technology (PRT) system uses riboflavin and ultraviolet light and is currently approved and used in Europe for the treatment of platelets and plasma. Mirasol treatment is intended to reduce the infectious pathogen load and to inactivate leukocytes in blood products. Our objective was to evaluate buffy coat platelet concentrates (BCPCs) prepared with platelet additive solution (PAS) and treated with the Mirasol system and to examine the effects on platelet cell quality during storage.
  
  
  METHODS
  26 BCPCs were prepared and split, creating 13 paired control and test units. The test units were treated with the Mirasol system and the platelet quality was assessed in all units over 7 days of storage.
  
  
  RESULTS
  All products met the incoming specifications for Mirasol treatment, and the pH of all Mirasol-treated BCPCs in PAS met the requirements of the Council of Europe guidelines throughout storage. Analysis of lactate production and glucose consumption rates, CD62p expression and cytokines indicates enhanced cellular metabolism in treated platelets, but the levels were within previously published ranges.
  
  
  CONCLUSIONS
  While Mirasol-treated BCPCs in PAS had increased metabolism and activation compared to controls, the results indicate that these units can be stored for 7 days with acceptable cell quality.
authors: Centro de Transfusion de Galicia, Santiago de Compostela, Spain.
authors: Azucena
authors: A
authors: Castrillo
authors: Marcia
authors: M
authors: Cardoso
authors: Lindsay
authors: L
authors: Rouse
keywords: Buffy coat platelets; Mirasol; PAS-IIIM; Pathogen reduction technology
references: Transfus Med Hemother. 2011;38(1):8-18
references: 21779202
references: Transfus Med Rev. 2008 Jan;22(1):1-34
references: 18063190
references: Transfusion. 2010 Nov;50(11):2362-75
references: 20492615
references: Blood Transfus. 2010 Jul;8(3):186-92
references: 20671879
references: Nat Med. 2004 Dec;10(12 Suppl):S98-109
references: 15577938
references: Vox Sang. 2009 Jul;97(1):26-33
references: 19302416
references: Transfusion. 2010 Nov;50(11):2461-73
references: 20497512
references: Transfusion. 2011 Feb;51(2):344-56
references: 20723169
references: Transfus Apher Sci. 2008 Aug;39(1):75-82
references: 18602343
references: Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11877-82
references: 8876231
references: Transfusion. 2008 Jul;48(7):1333-41
references: 18298600
references: Transfusion. 1999 Nov-Dec;39(11-12):1179-84
references: 10604243
references: Transfusion. 2011 Jul;51(7):1397-404
references: 21155832
references: Vox Sang. 2010 Aug 1;99(2):193-4
references: 20345519
references: Vox Sang. 2006 May;90(4):279-85
references: 16635070
references: Transplantation. 2007 Nov 15;84(9):1174-82
references: 17998874
references: Transfusion. 2011 Jul;51(7):1369-76
references: 21736571
references: Transfusion. 2010 Oct;50(10):2210-9
references: 20456708
references: Transfusion. 2005 Aug;45(8):1335-41
references: 16078923
references: Transfusion. 2010 Nov;50(11):2489-98
references: 20529002